KR100328975B1 - Whitening composition including the myrrh extract - Google Patents
Whitening composition including the myrrh extract Download PDFInfo
- Publication number
- KR100328975B1 KR100328975B1 KR1019990037387A KR19990037387A KR100328975B1 KR 100328975 B1 KR100328975 B1 KR 100328975B1 KR 1019990037387 A KR1019990037387 A KR 1019990037387A KR 19990037387 A KR19990037387 A KR 19990037387A KR 100328975 B1 KR100328975 B1 KR 100328975B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- whitening
- myrrh
- effect
- composition
- Prior art date
Links
- 230000002087 whitening effect Effects 0.000 title claims abstract description 56
- 229940081859 myrrh extract Drugs 0.000 title claims abstract description 35
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 239000000284 extract Substances 0.000 claims abstract description 112
- 239000002537 cosmetic Substances 0.000 claims abstract description 39
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 claims abstract description 25
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 claims abstract description 25
- 239000004480 active ingredient Substances 0.000 claims abstract description 18
- 229940069445 licorice extract Drugs 0.000 claims abstract description 11
- 240000002045 Guettarda speciosa Species 0.000 claims abstract description 5
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 5
- 235000011803 sesame oil Nutrition 0.000 claims abstract description 5
- 239000008159 sesame oil Substances 0.000 claims abstract description 5
- 229940022584 angelica seed extract Drugs 0.000 claims abstract description 4
- 240000007890 Leonurus cardiaca Species 0.000 claims abstract 4
- 230000000694 effects Effects 0.000 abstract description 14
- 240000007311 Commiphora myrrha Species 0.000 abstract description 8
- 235000006965 Commiphora myrrha Nutrition 0.000 abstract description 7
- 230000019612 pigmentation Effects 0.000 abstract description 7
- 235000007265 Myrrhis odorata Nutrition 0.000 abstract description 5
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 description 25
- 241000207925 Leonurus Species 0.000 description 21
- 235000015097 nutrients Nutrition 0.000 description 21
- 238000000034 method Methods 0.000 description 18
- 239000000126 substance Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000000419 plant extract Substances 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 10
- 235000008935 nutritious Nutrition 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- 102000003425 Tyrosinase Human genes 0.000 description 8
- 108060008724 Tyrosinase Proteins 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 238000002386 leaching Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 208000012641 Pigmentation disease Diseases 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000010865 sewage Substances 0.000 description 7
- 239000003990 capacitor Substances 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 241000411851 herbal medicine Species 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 5
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 5
- 229960004705 kojic acid Drugs 0.000 description 5
- 230000008099 melanin synthesis Effects 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 235000004347 Perilla Nutrition 0.000 description 3
- 244000124853 Perilla frutescens Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000001467 acupuncture Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 210000002752 melanocyte Anatomy 0.000 description 3
- 230000003061 melanogenesis Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 240000000233 Melia azedarach Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241001078983 Tetradium ruticarpum Species 0.000 description 2
- 229960000271 arbutin Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- 239000012454 non-polar solvent Substances 0.000 description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 2
- 238000005325 percolation Methods 0.000 description 2
- 210000004694 pigment cell Anatomy 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- FXEDIXLHKQINFP-UHFFFAOYSA-N 12-O-tetradecanoylphorbol-13-acetate Natural products CCCCCCCCCCCCCC(=O)OC1CC2(O)C(C=C(CO)CC3(O)C2C=C(C)C3=O)C4C(C)(C)C14OC(=O)C FXEDIXLHKQINFP-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000544270 Angelica acutiloba Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 150000000996 L-ascorbic acids Chemical class 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 235000003228 Lactuca sativa Nutrition 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 240000002817 Leonurus sibiricus Species 0.000 description 1
- 235000002434 Leonurus sibiricus Nutrition 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- 241000218922 Magnoliophyta Species 0.000 description 1
- 229940124200 Melanin inhibitor Drugs 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 244000226566 Psoralea corylifolia Species 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 235000019892 Stellar Nutrition 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000006049 herbal material Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000036564 melanin content Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
Abstract
본 발명은 피부 미백 효과가 우수한 조성물에 관한 것으로, 더욱 자세하게는 몰약 추출물을 유효성분으로 포함하는 것을 특징으로 하는 미백용 조성물에 관한 것이다.The present invention relates to a composition for excellent skin whitening effect, and more particularly to a whitening composition comprising a myrrh extract as an active ingredient.
본 발명에 따른 몰약 추출물을 함유한 미백용 조성물은 사람에게 사용했을 때 매우 안전하면서도 색소침착을 감소시키는 효과가 우수하다. 한편, 본 발명에 의한 몰약 추출물을 파고지 추출물, 오수유 추출물, 천련자 추출물, 익모초씨 추출물, 일당귀씨 추출물, 익모초 추출물, 일당귀 추출물 및 감초 추출물로 이루어진 군으로 부터 선택된 하나 이상의 추출물과 혼합한 혼합 추출물을 함유하면 미백 효과면에서 상승효과가 나타난다. 또한, 본 발명에 따른 몰약 추출물 및 혼합 추출물은 제품의 안정성에 영향을 미치지 않는 농도에서 색소침착을 감소시키는 효과가 있으므로 미백화장료에 유효농도로 사용할 수 있다.The composition for whitening containing a myrrh extract according to the present invention is very safe when used in humans and has an excellent effect of reducing pigmentation. Meanwhile, a mixed extract of the myrrh extract according to the present invention is mixed with one or more extracts selected from the group consisting of pagoji extract, sesame oil extract, cheonnyeonja extract, motherwort seed extract, daily Angelica seed extract, motherwort extract, daily Angelica extract and licorice extract If contained, synergistic effect is shown in terms of whitening effect. In addition, myrrh and mixed extract according to the present invention has an effect of reducing pigmentation at a concentration that does not affect the stability of the product can be used as an effective concentration in whitening cosmetics.
Description
본 발명은 피부 미백 효과가 우수한 조성물에 관한 것으로, 더욱 자세하게는 몰약 추출물을 함유하는 것을 특징으로 하는 미백용 조성물에 관한 것이다.The present invention relates to a composition having excellent skin whitening effect, and more particularly to a whitening composition comprising a myrrh extract.
사람의 피부색을 결정하는 데는 여러 요인들이 관여하는데, 그 중에서도 멜라닌 색소를 만드는 멜라노사이트(melanocyte)의 활동성, 혈관의 분포, 피부의 두께 및 카로티노이드, 빌리루빈 등의 인체 내외의 색소 함유 유무 등의 요인들이 중요하다. 특히, 가장 중요한 요인은 인체 내의 멜라노사이트에서 타이로시나제 등의 여러 효소가 작용하여 생성되는 멜라닌이라는 흑색 색소이다. 이 멜라닌 색소의 형성에는 유전적 요인, 호르몬 분비, 스트레스 등과 관련된 생리적 요인, 및 자외선 조사 등과 같은 환경적 요인 등이 영향을 미친다.Many factors are involved in determining the skin color of humans, including the activity of melanocytes that make melanin, the distribution of blood vessels, the thickness of skin and the presence or absence of pigments in the body, such as carotenoids and bilirubin. It is important. In particular, the most important factor is a black pigment called melanin produced by the action of various enzymes such as tyrosinase in melanocytes in the human body. Genetic factors, physiological factors related to hormone secretion, stress, and the like, and environmental factors such as ultraviolet ray irradiation have an influence on the formation of this melanin pigment.
특히, 기미, 주근깨, 색소침착 등과 같은 피부색소 이상침착 증상과 자외선노출 등에 의해 발생된 과도한 멜라닌 색소침착을 치료 또는 경감시켜주기 위해서, 이전부터 아스코르빈산, 코지산, 알부틴, 하이드로퀴논, 글루타치온 또는 이들의 유도체, 타이로시나제 저해활성을 가진 물질들을 화장료나 의약품에 배합 사용하여 왔는데, 이들은 불충분한 미백효과, 피부에 대한 안전성 문제, 화장료에 배합시 제형 및 안정성 문제 등으로 인해 그 사용이 제한되고 있다.In particular, ascorbic acid, kojic acid, arbutin, hydroquinone, glutathione, or the like to treat or alleviate excessive melanin pigmentation caused by abnormal skin pigmentation symptoms such as blemishes, freckles, pigmentation, and UV exposure. These derivatives and substances with tyrosinase inhibitory activity have been used in cosmetics and pharmaceuticals, but their use is limited due to insufficient whitening effects, safety problems for skin, formulation and stability problems when formulated in cosmetics, etc. It is becoming.
한편, 현재 이들 기존 미백 효능 물질들 이외에 천연물 중에서 미백활성성분을 찾기 위한 연구가 계속 이루어지고 있는데, 그 중 상백피(일본공개특허 소55-44375, 소64-26507, 소64-83009, 평1-25687, 평5-139950, 한국공개특허 제92-002109호, 제97-021273호), 감초(일본공개특허 소60-214721, 소63-23809, 소64-63506, 평1-149706, 한국공개특허 제92-002109호, 제97-025601호) 등 다수의 식물추출물이 타이로시나제에 작용하여 멜라닌 생성을 억제한다는 사실이 밝혀졌으나, 이들 역시 안전성, 안정성, 변색 가능성 등의 측면에서 화장품이나 의약품에 유효농도 이상으로 사용하는 데는 많은 문제점을 갖고 있으며 만족할 만한 효과를 내지 못하는 실정이다.Meanwhile, in addition to these existing whitening efficacy substances, research is being conducted to find whitening active ingredients in natural products. Among them, Sangbaekpi (Japanese Patent Publication No. 55-44375, So64-26507, So64-83009, Pyeong1- 1) 25687, Hei 5-139950, Korean Laid-Open Patent Nos. 92-002109, 97-021273), Licorice (Japanese Laid-Open Patent Publication No. 60-214721, Small 63-23809, Small 64-63506, Flat 1-49706, Korean Publication Patent Nos. 92-002109, 97-025601) and many plant extracts have been found to act on tyrosinase to inhibit melanin production, but they also have cosmetics in terms of safety, stability, and discoloration. There are many problems in using the drug at an effective concentration or higher, and it does not produce a satisfactory effect.
한편, 종래에는 버섯 유래의 타이로시나제에 대한 저해 활성으로서 미백 물질을 검색하는 방법으로 멜라닌생성을 억제하는 물질을 검색하였다. 그러나, 버섯 유래의 타이로시나제는 사람의 멜라닌 합성을 주관하는 타이로시나제와는 그 구조면에서 크게 차이가 있기 때문에, 버섯 유래 타이로시나제로에 의한 검색으로서는 사람에게서 만족할 만한 효과를 보이는 미백물질을 찾아내기가 어렵다.On the other hand, conventionally, a substance that inhibits melanogenesis was searched by searching for a whitening substance as an inhibitory activity against tyrosinase derived from mushrooms. However, since tyrosinase derived from mushrooms is significantly different in structure from tyrosinase, which is responsible for the synthesis of human melanin, the search by mushroom-derived tyrosinase zero shows satisfactory effects in humans. Hard to find whitening material
이에 본 발명자들은 천연 추출물이 제품의 안정성 측면에서 높은 농도로 사용할 수 없음을 감안하여 낮은 농도에서도 미백효과를 발휘할 수 있는 식물 추출물을 찾고자 하였으며, 또한, 사람에게 유효한 멜라닌생성 억제물질을 검색하기 위해, 버섯 유래의 타이로시나제를 사용한 종래방법의 문제점을 극복하고자 개선된 방법인 멜엡 에세이(Mel-Ab assay)라는 세포 수준의 멜라닌 생합성 저해를 측정할 수 있는 방법을 도입하였다.Therefore, the inventors of the present invention have tried to find a plant extract that can exert a whitening effect even at low concentrations in view of the fact that a natural extract cannot be used at a high concentration in terms of stability of the product, and also, in order to search for a melanogenesis inhibitor that is effective for humans, In order to overcome the problems of the conventional method using a mushroom-derived tyrosinase, a method for measuring the inhibition of melanin biosynthesis at the cellular level, which is an improved method, called Mel-Ab assay, was introduced.
본 발명은 피부 미백 효과가 우수한 조성물에 관한 것으로, 더욱 자세하게는 몰약 추출물을 유효성분으로 하는 것을 특징으로 하는 미백용 조성물에 관한 것이다.The present invention relates to a composition having excellent skin whitening effect, and more particularly to a composition for whitening, characterized in that the myrrh extract as an active ingredient.
상기한 본 발명에 의한 몰약 추출물 함유 미백용 조성물은, 파고지 추출물, 오수유 추출물, 천련자 추출물, 익모초씨 추출물, 일당귀씨 추출물, 익모초 추출물, 일당귀 추출물 및 감초 추출물로 이루어진 군으로부터 선택된 하나 이상의 추출물을 더 첨가하여 미백 효과를 상승시킨 것을 특징으로 한다.먼저, 사람에게 유효한 멜라닌생성 억제물질을 검색하기 위해, 사람의 멜라노사이트와 유사하다고 할 수 있는 쥐 유래의 멜라노사이트(Mel-Ab)를 이용하여 여러 종류의 식물추출물에 대해 미백효과를 검색하였다.The composition for whitening myrrh extract-containing whitening according to the present invention, at least one extract selected from the group consisting of pagoji extract, sesame oil extract, cheonnyeonja extract, motherwort seed extract, daily Angelica seed extract, motherwort extract, daily Angelica extract and licorice extract It is characterized in that the whitening effect is increased by first adding. In order to search for a melanogenesis inhibitor that is effective for humans, a mouse-derived melanosite (Mel-Ab), which is similar to human melanocytes, can be used. The whitening effect of various plant extracts was searched.
그 결과, 몰약 추출물이 낮은 농도에서도 매우 우수한 멜라닌 생성 저해물질로서 역할할 뿐만 아니라, 사람 피부에 직접 도포한 결과 뚜렷한 미백효과를 발휘함을 발견하게 되어 본 발명을 완성하게 되었다[실험 1 및 2 참조].As a result, the myrrh extract not only acts as a very good melanin inhibitor at low concentrations, but also finds a clear whitening effect as a result of direct application to human skin, thus completing the present invention [see Experiments 1 and 2]. ].
따라서, 본 발명은 피부미백효과를 나타내기 위해, 몰약 추출물을 유효성분으로 포함하는 것을 특징으로 하는 조성물을 제공하고자 한다. 또한 본 발명은 피부미백효과를 나타내기 위해, 몰약 추출물에 파고지 추출물, 오수유 추출물, 천련자 추출물, 익모초씨 추출물, 일당귀씨 추출물, 익모초 추출물, 일당귀 추출물 및 감초 추출물로 이루어진 군으로부터 선택된 하나 이상의 추출물을 더 첨가하여 미백 효과를 상승시킨 것을 특징으로 하는 조성물을 제공하고자 한다.Therefore, the present invention is to provide a composition comprising a myrrh extract as an active ingredient, in order to exhibit a skin lightening effect. In addition, the present invention, in order to show the skin whitening effect, at least one extract selected from the group consisting of Pagoji extract, sesame oil extract, cheonnyeonja extract, motherwort seed extract, daily Angelica seed extract, motherwort extract, daily Angelica extract and licorice extract in myrrh extract It is to further provide a composition characterized in that the addition to increase the whitening effect.
이하, 아래에서는 상기한 목적을 달성할 수 있는 본 발명의 기술적 내용을 중심으로 한 미백용 조성물에 대하여 설명한다.Hereinafter, the composition for whitening centering on the technical content of this invention which can achieve the said objective is demonstrated.
본 발명에 사용된 한방 재료인 몰약은 몰약나무(Commiphora myrrha, C. molmol)의 나무 줄기에 상처를 내거나 또는 저절로 흘러내려 굳어진 방향성의 나무진이며 식물성 방부제로서 주로 구강의 감염에 많이 쓰이며 항균작용이 있고 수렴제, 구풍제, 건위제로도 사용된다.Myrrh, the herbal material used in the present invention, is a fragrant medicinal tree that is hardened by spontaneous wounds or spontaneously flows down the trunk of the myrrh tree ( Commiphora myrrha , C. molmol). It is also used as astringent, puncture, and dry matter.
파고지는 콩과식물 보골지(Psoralea corylifolia)의 종자로서 한방에서는 신장 및 생식기능을 돕고 외용으로 백전풍을 치료하며 뼈를 튼튼하게 하는 약효가 있다고 한다. Pagoji is a seed of Psoralea corylifolia , which is said to help renal and reproductive functions in Chinese medicine, to treat Baekjeok for external use, and to strengthen bones.
오수유는 산초나무과 식물인 오수유나무(Evodia officinalis,E. rutaecarpa)의 성숙되지 않은 열매로서 한방에서는 위를 따뜻하게 하고 통증을 멎게 하며 기의 순환을 조절하여 구토, 두통, 구내염, 치통 등을 치료하는데 사용된다. Fructus is an immature fruit of the medicinal herb , Evodia officinalis ( E. rutaecarpa ), which is used to treat vomiting, headaches, stomatitis, and toothache by warming the stomach, relieving pain, and regulating the circulation of the stomach. do.
천련자는 멀구슬나무 (Melia azedarach) 또는 당멀구슬나무 (M. toosendan)의 열매로서 예로부터 한방에서는 정장약, 진통약으로서 복통에 쓰이고, 구충약으로 사용되어 왔다.The medicinal herb is a fruit of Melia azedarach or M. toosendan, and has been used as a medicine for long-term use as a medicine and pain medicine in traditional medicine.
익모초 씨는 꿀풀과 식물인 익모초(Leonurus sibiricus)의 종자이다. 한편, 익모초는 한방에서 혈액순환을 돕고 산전산후의 보호약, 이뇨, 소화불량 등에 사용하고 상처치유의 목적으로 사용하지만, 그 종자는 약용으로 사용되지 않았다. 종자의 경우, 특이하게 정유 성분이 다량 함유되어 있다.Motherwort seed is a seed of the plant Lamiaceae ( Leonurus sibiricus ). On the other hand, motherwort is used to help blood circulation in herbal medicine, postnatal prenatal protection, diuresis, indigestion, etc. and for wound healing, but the seed was not used for medicinal purposes. In the case of seeds, the essential oil component is contained in a large amount.
일당귀씨는 미나리과 식물인 일당귀(Angelica acutiloba)의 종자이다. 한편, 일당귀는 한방에서 보혈, 강장, 진통, 진정약으로 사용되지만 그 종자는 약용으로 사용되지 않았다. 종자의 경우, 특이하게 정유 성분이 다량 함유되어 있다.One-danged seed is the seed of the Angelica acutiloba, a flowering plant. On the other hand, Dangdang is used as a blood, tonic, analgesic, sedative in herbal medicine, but its seed was not used for medicinal purposes. In the case of seeds, the essential oil component is contained in a large amount.
상기와 같은 천연식물은 이전에는 미백 효과가 있다고 알려져 있지 아니하였으며, 나아가, 상기 천연식물의 추출물을 미백효과를 위해 응용한 예도 없었다. 특히, 익모초 및 일당귀에 대하여 미백 효능와 관련한 특허들이 보고되어 있기는 하나, 그 종자인 씨에 대한 미백효과에 대해서는 응용된 바가 아직 없다. 비로서, 본 발명을 통해, 상기와 같은 천연식물의 추출물들이 낮은 농도에서도 미백효과를 나타낸다는 것이 밝혀지게 된 것이다.Such natural plants were not previously known to have a whitening effect, and furthermore, there was no example where the extract of the natural plant was applied for the whitening effect. In particular, although patents relating to whitening efficacy have been reported for motherwort and single-ear, no application has yet been applied for the whitening effect on the seed, seed. As a ratio, through the present invention, it has been found that the extracts of such natural plants have a whitening effect even at low concentrations.
본 발명에 사용된 천연식물로서 생약제는 이들의 용어 그 생약 자체를 한정한 것이 아니고, 각 천연식물의 "추출물"은 그 생약으로부터 침출, 전출하여 얻은 침출액, 또는 침출액을 다시 일부 또는 전부 농축하여 얻은 농축물, 또는 다시 그 농축물을 건조시켜 제조한 침제, 전제, 정기, 유동엑기스 등(이하 추출 엑기스라 함) 및 생약 중에 함유되고 있는 주효과를 발휘하는 화학물질 그 자체를 포함한다.As a natural plant used in the present invention, the herbal medicine does not limit the term herbal medicine itself, and the "extract" of each natural plant is obtained by partially or completely condensing the leaching liquid obtained by leaching or transferring from the herbal medicine, or again. Concentrates, or acupuncture, premises, regular, flow extracts (hereinafter referred to as "extract extract") prepared by drying the concentrates again, and the chemicals themselves exhibiting the main effect contained in the herbal medicine.
본 발명의 천연식물 추출 방법으로는 공지의 방법을 사용하는 것이 가능하다. 예를 들면, 본 발명에 따른 천연식물을 자연 건조 또는 강제 건조 등 임의의 방법으로 건조하여 잘게 자른 후, 물, 에탄올, 부탄올, 아세톤 등의 극성 용매; 에테르, 헥산, 벤젠, 클로로포름, 에틸아세테이트 등의 비극성 용매; 상기 극성 용매와 비극성 용매의 혼합 용매; 알카리 수 등의 용매, 또는 콩기름, 참기름 등의 식물유 등을 사용하여 냉침, 페르콜레이션(percolation), 온침 등의 임의의 방법에 의해서 침출 처리하여 유효 성분을 함유한 침출물을 얻는다. 침출 처리는 냉침과 페르콜레이션의 경우 12∼96 시간 정도, 온침의 경우는 사용하는 용매 등의 종류와 온도에 따라서 상이하나, 적합하게는 용매의 환류 온도에 가까운 온도로 0.5∼24 시간 정도 수행하는 것이 좋다. 특히, 본 발명의 추출물들은 함수 알코올에 침출한 틴크나 유동 엑기스 또는 엑기스의 것을 사용하는 것이 좋다.As a natural plant extraction method of the present invention, it is possible to use a known method. For example, the natural plant according to the present invention may be dried and chopped by any method such as natural drying or forced drying, followed by polar solvents such as water, ethanol, butanol and acetone; Nonpolar solvents such as ether, hexane, benzene, chloroform and ethyl acetate; A mixed solvent of the polar solvent and the nonpolar solvent; Using a solvent such as alkaline water, or vegetable oils such as soybean oil and sesame oil, the leaching treatment is carried out by any method such as cold sedimentation, percolation, and warm sedimentation to obtain a leaching substance containing the active ingredient. The leaching treatment is about 12 to 96 hours for cold acupuncture and percolation, and depending on the type and temperature of the solvent used for warm needles, but suitably about 0.5 to 24 hours at a temperature close to the reflux temperature of the solvent. Good to do. In particular, the extracts of the present invention is preferably used tincture, liquid extract or extract of the leaching in the hydrous alcohol.
한편, 본 발명에 따른 몰약 추출물 또는 혼합 추출물의 양은 화장료 조성물에 사용할 경우 0.01∼10.0 중량%인 것이 바람직하다. 0.01 중량% 이하에서는 그 효과를 기대할 수 없고, 10.0 중량% 이상에서는 안전성, 또는 제형상의 제조에 어려움이 있기 때문이다.On the other hand, the amount of myrrh or mixed extract according to the present invention is preferably 0.01 to 10.0% by weight when used in the cosmetic composition. It is because the effect cannot be expected in 0.01 weight% or less, and when it is 10.0 weight% or more, it is difficult to produce safety or formulation form.
또한, 본 발명에 따른 미백용 조성물은 상기한 추출물들 외에 본 발명이 목적으로 하는 주 효과를 손상시키지 않는 범위 내에서 바람직하게는 주 효과에 상승 효과를 줄 수 있는 다른 미백 성분 등을 함유하는 것도 무방하다. 이와 같은 성분으로서, 코직산, 아부틴, 아스코빅 산 유도체 등을 들 수 있다.In addition, the composition for whitening according to the present invention may also contain other whitening ingredients, etc., which may give a synergistic effect to the main effect, in addition to the above-mentioned extracts within the range of not impairing the main effect of the present invention. It's okay. Examples of such components include kojic acid, arbutin, ascorbic acid derivatives, and the like.
본 발명에 따른 천연식물 추출물은, 미백화장료 제형으로 침출액 또는 침출액의 에탄올 희석액을 그대로 도포하는 것이 적합하나, 통상의 한방제제, 침제, 전제, 틴크제, 엑기스제, 유동엑기스제, 시럽제, 연고, 크림제제 등의 내복 또는 외용의 제제로도 할 수 있다. 상기한 제제는 미백 효과를 증가시키기 위하여 피부 흡수 촉진 물질을 함유할 수 있다. 또한, 이들 제제의 투여량은 대상자의 연령, 증상, 투여 방법에 의해 상이하나, 외용제의 경우는 1일당 1.0∼3.0 ㎖로 이를 1일 1∼5회 도포하여 1개월 이상 계속하는 것이 좋다.Natural plant extract according to the present invention is suitable to apply the ethanol dilution of the leaching solution or leaching solution as a whitening cosmetic formulation as it is, but conventional herbal preparations, acupuncture, premise, tin, extract, fluid extract, syrup, ointment, It can also be used as an internal or external preparation such as a cream preparation. Such formulations may contain skin absorption promoting substances to increase the whitening effect. In addition, the dosage of these preparations varies depending on the subject's age, symptoms, and method of administration, but in the case of external preparations, 1.0 to 3.0 ml per day is preferably applied 1 to 5 times a day and continued for 1 month or more.
이하, 본 발명의 실시예에 의거하여 본 발명을 보다 구체적으로 설명한다. 그러나, 본 발명은 이들 실시예에 한정되는 것이 아님을 밝혀둔다.EMBODIMENT OF THE INVENTION Hereinafter, this invention is demonstrated more concretely based on the Example of this invention. However, it should be noted that the present invention is not limited to these examples.
천연식물 추출물의 제조Preparation of Natural Plant Extracts
1. 몰약 추출물의 제조몰약 50g을 세절하여 건조중량에 대하여 95% 함수 알코올 100㎖를 가한다. 냉각콘덴서가 장치되어 유효성분이 증발되는 것을 방지한 상태에서 50∼100℃로 10시간 가열하여 유효성분을 추출, 여과하고 완전히 감압농축하여 건조하여 4.5g의 몰약 추출물을 얻었다. 제조된 몰약 추출물은 점성이 있는 적색 액상의 페이스트 형태를 띠며, 독특한 향취를 지닌다.1. Preparation of Myrrh Extract 50 g of myrrh was cut into 100 ml of 95% hydrous alcohol based on dry weight. Cooling capacitor was installed to prevent evaporation of the active ingredient in a state of heating for 10 hours to 50 ~ 100 ℃ to extract the active ingredient, filtered and concentrated under reduced pressure completely to obtain 4.5g myrrh extract. The prepared myrrh extract has the form of a viscous red liquid paste and has a unique odor.
2. 파고지 추출물의 제조2. Preparation of Pagoji Extract
파고지 50g을 세절하여 건조중량에 대하여 95% 함수 알코올 100㎖를 가한다. 냉각콘덴서가 장치되어 유효성분이 증발되는 것을 방지한 상태에서 50∼100℃로 10시간 가열하여 유효성분을 추출, 여과하고 완전히 감압농축하여 건조하여 3.7g의 파고지 추출물을 얻었다. 제조된 파고지 추출물은 점성이 있는 갈색 액상의 페이스트 형태를 띠며, 독특한 향취를 지닌다.50 g of shredded paper is chopped and 100 ml of 95% hydrous alcohol is added to the dry weight. A cooling capacitor was installed to prevent evaporation of the active ingredient, and then heated to 50-100 ° C. for 10 hours to extract the active ingredient, filtered, concentrated under reduced pressure, and dried to obtain 3.7 g of pagoji extract. Pagoji extract prepared in the form of a viscous brown liquid paste, has a unique odor.
3. 오수유 추출물의 제조3. Preparation of Sewage Extract
오수유 50g을 세절하여 건조중량에 대하여 95% 함수 알코올 100㎖를 가한다. 냉각콘덴서가 장치되어 유효성분이 증발되는 것을 방지한 상태에서 50∼100℃로 10시간 가열하여 유효성분을 추출, 여과하고 완전히 감압농축하여 건조하여 6.3g의 오수유 추출물을 얻었다. 제조된 오수유 추출물은 점성이 있는 적색 액상의 페이스트 형태를 띠며, 독특한 향취를 지닌다.Cut 50 g of sewage oil and add 100 ml of 95% hydrous alcohol to dry weight. A cooling capacitor was installed to prevent evaporation of the active ingredient, and then heated to 50-100 ° C. for 10 hours to extract the active ingredient, filtered, and concentrated under reduced pressure to obtain 6.3 g of effluent oil. The prepared sewage oil extract has the form of a viscous red liquid paste and has a unique odor.
4. 천련자 추출물의 제조4. Preparation of Stellar Extract
천련자 50g을 세절하여 건조중량에 대하여 95% 함수 알코올 100㎖를 가한다. 냉각콘덴서가 장치되어 유효성분이 증발되는 것을 방지한 상태에서 50∼100℃로 10시간 가열하여 유효성분을 추출, 여과하고 완전히 감압농축하여 건조하여 2.1g의 천련자 추출물을 얻었다. 제조된 천련자 추출물은 점성이 있는 갈색 액상의 페이스트 형태를 띠며, 독특한 향취를 지닌다.Cut 50 g of the puncturer and add 100 ml of 95% hydrous alcohol to dry weight. A cooling capacitor was installed to prevent evaporation of the active ingredient, and heated to 50 to 100 ° C. for 10 hours to extract the active ingredient, filter it, and concentrated under reduced pressure to dry it to obtain 2.1 g of Stylus extract. The prepared lotus leaf extract has the form of a viscous brown liquid paste and has a unique odor.
5. 익모초씨 추출물의 제조5. Preparation of Motherwort Seed Extract
익모초씨 10g을 건조중량에 대하여 95% 함수 알코올 100㎖를 가한다. 냉각콘덴서가 장치되어 유효성분이 증발되는 것을 방지한 상태에서 50∼100℃로 10시간 가열하여 유효성분을 추출, 여과하고 완전히 감압농축하여 건조하여 0.25g의 익모초씨 추출물을 얻었다. 제조된 익모초씨 추출물은 점성이 있는 짙은 갈색의 액상의 페이스트 형태를 띠며, 독특한 향취를 지닌다.10 g of motherwort seed is added to 100 ml of 95% hydrous alcohol with respect to dry weight. A cooling capacitor was installed to prevent evaporation of the active ingredient, and then heated to 50 to 100 ° C. for 10 hours to extract the active ingredient, filtered, concentrated under reduced pressure, and dried to obtain 0.25 g of motherwort seed extract. The motherwort seed extract prepared is in the form of a viscous dark brown liquid paste and has a unique odor.
6. 일당귀씨 추출물의 제조6. Preparation of Iltangguise Seed Extract
일당귀씨 10g을 건조중량에 대하여 95% 함수 알코올 100㎖를 가한다. 냉각콘덴서가 장치되어 유효성분이 증발되는 것을 방지한 상태에서 50∼100℃로 10시간 가열하여 유효성분을 추출, 여과하고 완전히 감압농축하여 건조하여 0.3g의 몰약추출물을 얻었다. 제조된 일당귀씨 추출물은 점성이 있는 갈색 액상의 페이스트 형태를 띠며, 독특한 향취를 지닌다.7. 익모초, 일당귀, 감초 추출물의 제조상기 추출물들은 당업계에 공지된 바에 따라 제조한다.100 g of 95% hydrous alcohol is added to the dry weight of 10 g of perilla seed. A cooling capacitor was installed to prevent evaporation of the active ingredient, and then heated to 50 to 100 ° C. for 10 hours to extract and filter the active ingredient, concentrated under reduced pressure, and dried to obtain 0.3 g of myrrh. The manufactured Dang-Dang-Gui Seed extract has the form of a viscous brown liquid paste and has a unique odor. Preparation of Motherwort, Daily Angelica, Licorice Extract The extracts are prepared according to what is known in the art.
<실험 1; 천연식물 추출물의 미백작용 스크리닝><Experiment 1; Whitening Screening of Natural Plant Extracts>
C57BL/6 마우스에서 유래된 쥐의 색소세포를, 둘베코 변형-이글스 배지(Dulbeccos modified Eagles media; DMEM)에 10% PBS(fetal bovine serum), 10nM 12-O-테트라데카노일포르볼-13-아세테이트(12-O-tetradecanoylphorbol-13-acetate), 1nM 콜레라 독소(cholera toxin)를 첨가한 배지에서 37℃, 5% CO2조건으로 배양하였다. 24개 웰 플래이트(well plate)에 105세포/웰의 농도로 세포를 배양하고 세포의 부착을 확인한 뒤, 세포 배양액에 상기 추출한 시험물질을 표 1과 같이 배합하여 최종농도 0.001% 내지 0.004% 로 하여 3일 동안 배양하였다. 배양액을 제거하고, PBS로 세척한 후 1N NaOH로 세포를 녹여 400㎚에서 흡광도를 측정하였다. 시험물질을 첨가하지 않은 세포를 대조군으로 하여, 대조군에서의 멜라닌 함량과 비교하여 시험물질의 멜라닌 생성 저해정도를 측정하여 미백효과를 측정하였다.Rat pigment cells derived from C57BL / 6 mice were placed in Dulbeccos modified Eagles media (DMEM) with 10% PBS (fetal bovine serum), 10 nM 12-O-tetradecanoylphorball-13-. Incubated at 37 ° C. and 5% CO 2 in medium containing acetate (12-O-tetradecanoylphorbol-13-acetate) and 1 nM cholera toxin. After culturing the cells at a concentration of 10 5 cells / well in 24 well plates and confirming cell adhesion, the extracted test substances were mixed in the cell culture medium as shown in Table 1 to a final concentration of 0.001% to 0.004%. Incubated for 3 days. The culture solution was removed, washed with PBS, and the cells were dissolved with 1N NaOH and absorbance was measured at 400 nm. Using the cells without the test substance as a control, the whitening effect was measured by measuring the degree of inhibition of melanin production of the test substance compared to the melanin content in the control.
또한, 비교예로, 상기와 같은 방법으로 추출한 상백피 추출물, 감초 추출물, 익모초 추출물, 일당귀 추출물 및 코지산에 대하여 C57BL/6 마우스 색소세포를 이용하여 동일한 방법으로 미백효과를 측정하였다.In addition, as a comparative example, the whitening effect of the lettuce extract, licorice extract, motherwort extract, perilla extract and kojic acid extracted by the same method was measured using the C57BL / 6 mouse pigment cells in the same manner.
이로부터 얻은 식물 추출물의 멜라닌 생성 저해 효과 결과를 하기 표 1에 나타내었다.The melanin production inhibitory effect of the plant extract obtained from it is shown in Table 1 below.
표 1에서 보는 바와 같이 본 발명에 의한 몰약 추출물 등은 0.001%의 낮은 농도에서 매우 높은 멜라닌 생성 저해효과를 나타내었다. 또한, 이들 추출물들은 이미 미백효과가 우수한 것으로 알려진 코지산 등에 비해 낮은 농도에서 월등하게 효과가 우수하였다. 특히, 익모초씨 추출물과 일당귀씨 추출물은 미백 효과가 있다고 알려진 익모초 추출물, 일당귀 추출물에 비하여 상대적으로 미백효과가 우수하였다. 또한, 본 발명에 따른 몰약 추출물에 더하여 파고지 추출물과 같은 다른 천연식물 추출물 및 감초 추출물과 같은 공지의 추출물을 선택적으로 첨가하였을 때 미백 효과가 상승되는 결과를 얻었다.As shown in Table 1, the myrrh extract according to the present invention showed a very high melanin production inhibitory effect at a low concentration of 0.001%. In addition, these extracts were superior in effect at low concentrations compared to kojic acid, which is already known to have excellent whitening effect. In particular, the motherwort seed extract and Ildang eared seed extract were relatively superior in whitening effect as compared to motherwort extract and Ildang ear extract known to have a whitening effect. In addition to the myrrh extract according to the present invention, the whitening effect was increased when selectively added other natural plant extracts, such as pagoji extract and well-known extracts, such as licorice extract.
[실시예 1: 몰약 추출물을 함유한 영양화장수 제조]Example 1 Preparation of Nutritious Cosmetic Water Containing Myrrh Extract
몰약 추출물을 함유한 영양화장수의 처방예는 표 2와 같다.Prescription examples of nutrient cosmetics containing myrrh extract are shown in Table 2.
[실시예 2: 파고지 추출물을 함유한 영양화장수 제조]Example 2 Preparation of Nutritious Cosmetic Water Containing Pagoji Extract
실시예 1과 동일한 처방방법으로 제조하되, 상기 몰약 추출물을 상기 제조된 파고지 추출물로 대체하여 영양화장수를 제조하였다.Prepared by the same prescription method as in Example 1, by replacing the myrrh extract with the prepared pagoji extract was prepared nutrient cosmetics.
[실시예 3: 오수유 추출물을 함유한 영양화장수 제조]Example 3 Preparation of Nutritious Cosmetic Water Containing Sewage Oil Extract
실시예 1과 동일한 처방방법으로 제조하되, 상기 파고지 추출물을 상기 제조된 오수유 추출물로 대체하여 영양화장수를 제조하였다.Prepared by the same prescription method as in Example 1, by replacing the pagoji extract with the prepared sewage extract was prepared nutrient cosmetic water.
[실시예 4: 천련자 추출물을 함유한 영양화장수 제조]Example 4 Preparation of Nutritious Cosmetic Water Containing Cheonnyeonja Extract
실시예 1과 동일한 처방방법으로 제조하되, 상기 파고지 추출물을 상기 제조된 천련자 추출물로 대체하여 영양화장수를 제조하였다.Prepared by the same prescription method as in Example 1, by replacing the pagoji extract with the prepared cheonnyeonja extract was prepared nutrient cosmetics.
[실시예 5: 익모초씨 추출물을 함유한 영양화장수 제조]Example 5 Preparation of Nutritious Cosmetic Water Containing Motherwort Seed Extract
실시예 1과 동일한 처방방법으로 제조하되, 상기 파고지 추출물을 상기 제조된 익모초씨 추출물로 대체하여 영양화장수를 제조하였다.Prepared by the same prescription method as in Example 1, by replacing the pagoji extract with the prepared motherwort seed extract was prepared nutrient cosmetics.
[실시예 6: 일당귀씨 추출물을 함유한 영양화장수 제조]Example 6 Preparation of Nutritious Cosmetic Water Containing Extracts
실시예 1과 동일한 처방방법으로 제조하되, 상기 파고지 추출물을 상기 제조된 일당귀씨 추출물로 대체하여 영양화장수를 제조하였다.Prepared by the same prescription method as in Example 1, by replacing the Pagoji extract with the prepared Dangdangwi seed extract was prepared nutrient cosmetics.
[실시예 7: 몰약 추출물과 파고지 추출물을 함유한 영양화장수 제조]Example 7 Preparation of Nutrients Containing Myrrh Extract and Pagoji Extract
실시예 1과 동일한 처방방법으로 제조하되, 상기 몰약 추출물 대신에 상기 몰약 추출물과 상기 파고지 추출물을 각각 0.5씩 혼합한 혼합 추출물을 함유한 영양화장수를 제조하였다.Prepared by the same prescription method as in Example 1, instead of the myrrh extract was prepared nutrient cosmetics containing a mixed extract of 0.5 each of the myrrh extract and the pagoji extract was mixed.
[실시예 8: 몰약 추출물, 파고지 추출물 및 오수유 추출물을 함유한 영양화장수 제조]Example 8 Preparation of Nutritious Cosmetic Water Containing Myrrh Extract, Pagoji Extract and Sewage Extract
실시예 1과 동일한 처방방법으로 제조하되, 상기 몰약 추출물 대신에 상기 몰약 추출물과 상기 파고지 추출물과 상기 오수유 추출물을 각각 0.5씩 혼합한 혼합 추출물을 함유한 영양화장수를 제조하였다.Prepared by the same prescription method as in Example 1, instead of the myrrh extract was prepared nutrient cosmetics containing a mixed extract of 0.5 each of the myrrh extract, the pagoji extract and the sewage oil extract.
[실시예 9: 몰약추출물, 파고지 추출물, 천련자 추출물, 공지의 감초 추출물을 함유한 영양화장수 제조]Example 9 Preparation of Nutrients Extract Containing Myrrh Extract, Pagoji Extract, Lilium Extract, and Licorice Extract
실시예 1과 동일한 처방방법으로 제조하되, 상기 몰약 추출물 대신에 상기 몰약 추출물과 상기 파고지 추출물과 상기 천련자 추출물과 공지의 감초 추출물을 각각 0.5씩 혼합한 혼합 추출물을 함유한 영양화장수를 제조하였다.Prepared by the same prescription method as in Example 1, instead of the myrrh extract was prepared nutrient cosmetics containing a mixed extract of 0.5 each of the myrrh extract, the pagoji extract, the cheongija extract and a known licorice extract.
[실시예 10: 익모초씨 추출물과 익모초 추출물을 함유한 영양화장수 제조]Example 10 Preparation of Nutritious Cosmetic Water Containing Motherwort Seed Extract and Motherwort Extract
실시예 1과 동일한 처방방법으로 제조하되, 상기 몰약 추출물을 상기 제조된 익모초씨 추출물과 공지의 익모초 추출물로 각각 0.5씩 혼합, 대체하여 영양화장수를 제조하였다.Prepared by the same prescription method as in Example 1, the myrrh extract was mixed with each of the prepared motherwort seed extract and known motherwort extract, respectively 0.5, and replaced to prepare nutrient cosmetics.
[실시예 11: 일당귀씨 추출물과 일당귀 추출물을 함유한 영양화장수 제조]Example 11 Preparation of Nutritious Cosmetic Water Containing Extracts of Il-Dang-Gui
실시예 1과 동일한 처방방법으로 제조하되, 상기 몰약 추출물을 상기 제조된 일당귀씨 추출물과 공지의 일당귀 추출물로 각각 0.5씩 혼합, 대체하여 영양화장수를 제조하였다.Prepared by the same prescription method as in Example 1, by mixing and replacing each of the myrrh extract with 0.5 mg each of the prepared perilla extract and known periwinkle extract to prepare nutrient cosmetics.
[비교예 1: 코지산을 함유한 영양화장수 제조]Comparative Example 1: Preparation of Nutritious Cosmetic Water Containing Kojisan
실시예 1과 동일한 처방방법으로 제조하되, 상기 몰약 추출물 대신 코지산으로 대체하여 영양화장수를 제조하였다.It was prepared by the same prescription method as in Example 1, but instead of kojic acid instead of the myrrh extract was prepared for nutrient cosmetics.
<실험 2; 천연추출물을 함유한 제조 처방의 인체에 대한 미백 효과시험 ><Experiment 2; Whitening Effect Test on Human Body of Prescription Formulation Containing Natural Extracts >
건강한 남녀 20명을 실험대상자로 하여, 양팔 하박부에 직경 1.5㎝의 구멍 6개가 뚫린 불투명 테이프를 부착한 뒤 각 피검자의 최소홍반량의 1.5~2배 정도의 자외선(UVB)을 조사하여 피부의 흑화를 유도하고 나서 시험물질들을 함유한 영양화장수(실시예 1 내지 11, 비교예 1)를 8주간, 하루에 2회씩(아침, 저녁), 주 5일 바르게 하였다. 두 달 후에 색차계를 이용하여 피부의 명암을 측정하였다. 대조군은, 실시예 1과 동일한 방법으로 제조하되 천연식물 추출물이 구성성분에 첨가되지 아니한 영양화장수를 도포하여 실험하였다.Using 20 healthy men and women as test subjects, an opaque tape with 6 holes of 1.5 cm in diameter was attached to the lower arm of each arm and irradiated with UVB (1.5-2 times the minimum erythema) of each subject. After induction of blackening, nutritional longevity containing the test substances (Examples 1 to 11 and Comparative Example 1) was corrected twice a day for 8 weeks (morning and evening) and 5 days a week. Two months later, the contrast of the skin was measured using a color difference meter. The control group was prepared in the same manner as in Example 1, but was tested by applying nutrient cosmetics that the natural plant extract is not added to the components.
색차계(미놀타 CR2002)를 사용하여 피부의 흑백정도를 측정하여 효과를 판정하였다. 색을 표시하는 데에는 L*a*b*표색계를 쓰며, 본 실험에서는 주로 L*값(명도)을 지표로 하였다. L*값은 정해진 백판으로 교정하며, 측정은 1개소에 5회 이상 측정을 되풀이함으로서 색소침착부를 균등하게 측정하였다. 시험물질을 함유한 영양화장수를 도포하기 시작할 시점과 8주 후 상기 영양화장수의 도포를 완료한 시점에서의 피부색의 차이 (ΔL*)를 구하고 이 값으로 효과를 판정하였다. 그 결과 천연식물 추출물의 사람 수준에서의 미백효과를 하기 표3과 같이 나타내었다.The effect was determined by measuring the degree of black and white of the skin using a color difference meter (Minolta CR2002). L * a * b * color system is used to display the color. In this experiment, L * value (brightness) is mainly used as an index. The L * value was calibrated with a predetermined white board, and the measurement was performed by measuring the pigmentation portion evenly by repeating the measurement five times or more at one place. The difference in skin color (ΔL * ) at the time of starting application of the nutrient cosmetics containing the test substance and the completion of the application of the nutrient cosmetics after 8 weeks was determined and the effect was determined using this value. As a result, the whitening effect at the human level of the natural plant extract is shown in Table 3.
ΔL*= 도포후 X일 후의 L*- 도포개시할 때의 L*값ΔL * = L * after X days after application - L * values at the time of start of the coating
표 3에서 보듯이, 본 발명에 따른 몰약 추출물 등을 함유한 영양화장수를 사용했을 때, 피부 색소 침착의 감소를 확인할 수 있었다. 또한 몰약 추출물에 파고지 추출물과 같은 다른 천연 추출물 및 감초 추출물과 같은 공지의 천연 추출물을 혼합 제조한 처방의 경우, 미백 효과가 상승되는 결과를 보였다. 이 실험 도중 피실험자에게 식물추출물을 함유한 영양화장수 사용에 의해서는 아무런 자극이 나타나지 않았다.As shown in Table 3, when the nutrient cosmetics containing the myrrh extract and the like according to the present invention was used, it was confirmed that the reduction of skin pigmentation. In addition, in the case of the formulation prepared by mixing the myrrh extract with other natural extracts such as pagoji extract and known natural extracts such as licorice extract, the whitening effect was shown to be increased. During this experiment, the subject showed no irritation by the use of nutrient-containing water containing plant extracts.
<실험 3: 안전성 시험, 인체 첩포 시험><Experiment 3: safety test, human patch test>
본 발명에 따른 조성물에 대하여 피부 자극 정도를 알아보기 위하여, 실시예 1 내지 11에 따른 미백화장료에 대한 피부 첩포시험을 피검자 15명에게 실시하였다. 핀챔버(fin chamber)에 실시예 1 내지 11의 각 영양화장수를 20㎕ 가하여 인체 상박부에 24시간 첩포하고, 첩포 제거 후 1 시간 이내에 피부반응을 검사하고, 다음날(48시간 후) 다시 검사하였다. 피부 반응 판정은 표 4의 검사 기준에 의해 판정하고, 아래 공식에 따라 평균반응율을 계산하였다.In order to determine the degree of skin irritation with respect to the composition according to the present invention, a skin patch test on the whitening cosmetics according to Examples 1 to 11 was performed on 15 subjects. 20 µl of each of the nutrients of Examples 1 to 11 was added to a fin chamber and patched to the upper arm of the human body for 24 hours, the skin reaction was examined within 1 hour after the patch was removed, and the next day (after 48 hours) was examined again. . The skin response was judged by the inspection criteria of Table 4, and the average response rate was calculated according to the following formula.
예를들면, 실시예1의 평균반응율은 다음과 같이 계산하였다.For example, the average reaction rate of Example 1 was calculated as follows.
[(14명×0점+1명×1점+0명×2점+0명×3점+0명×4점)+(15명×0점+0명×1점+0명×2점+0명×3점+0명×4점)]×100/(2회×4점×15명)= 0.83%((14 x 0 points + 1 x 1 point + 0 x 2 points + 0 x 3 points + 0 x 4 points) + (15 x 0 points + 0 x 1 point + 0 x 2) Dot + 0 points x 3 points + 0 points x 4 points) x 100 / (2 x 4 points x 15 persons) = 0.83%
그 이외 실시예 2 내지 실시예 11도 상기와 같은 방법으로 평균반응율을 계산하였다. 그 결과 미백화장료 조성물의 인체 첩포시험 결과를 하기 표 5에 나타내었다.In addition, in Example 2 to Example 11 was also calculated the average reaction rate in the same manner as described above. As a result, the results of the human patch test of the whitening cosmetic composition are shown in Table 5 below.
1 미만: 무자극, 1∼3 미만 : 경자극, 3∼5 미만 : 중자극,Less than 1: non-irritating, less than 1 to 3: hard stimulation, less than 3 to 5: medium stimulation,
5 이상: 강자극5 or higher: strong stimulus
표 5에 의해 알 수 있듯이, 본 발명에 따른 미백 화장료 조성물은 무자극 범위에 속하므로 인체에 안전한 물질이라고 할 수 있다.As can be seen from Table 5, the whitening cosmetic composition according to the present invention can be said to be a safe substance to the human body because it belongs to the non-irritating range.
<실험 5: 안정성 시험><Experiment 5: Stability Test>
본 발명에 따른 조성물에 대한 안정성 정도를 알아보고자, 실시예 1 내지 11에 따른 미백 화장료에 대한 안정성 시험을 실시하였다.In order to determine the degree of stability for the composition according to the present invention, a stability test for the whitening cosmetics according to Examples 1 to 11 was carried out.
실시예 1 내지 11의 영양화장수를 상온, 4℃ 냉장고, 37℃ 항온조 및 45℃ 항온조에 3달간 방치하였고, 3개월 경과 후, 각 제형의 변화를 관찰하였다. 제형의 분리정도에 따라 '0'(안정), '+/-' (약간불안정) ,'+'(불안정)로 표시하였다.Nutrients of Examples 1 to 11 were allowed to stand for 3 months in a room temperature, 4 ℃ refrigerator, 37 ℃ thermostat and 45 ℃ thermostat, after 3 months, the change of each formulation was observed. According to the degree of separation of the formulation, '0' (stable), '+/-' (slightly unstable), and '+' (unstable).
표 6에서 보여 주듯이, 본 발명에 따른 미백화장료 조성물들은 상온(25℃), 냉온(4℃도), 37℃ 및 45℃에서 안정하였다.As shown in Table 6, the whitening cosmetic compositions according to the present invention were stable at room temperature (25 ° C), cold (4 ° C), 37 ° C and 45 ° C.
본 발명에 따른 실시예 및 실험에서 알 수 있는 바와 같이, 본 발명에 따른 몰약 추출물 또는 혼합 추출물을 함유한 미백용 조성물은 사람에게 사용했을 때 매우 안전하면서도 색소침착을 감소시키는 효과가 우수하다. 한편, 몰약 추출물과 기타 다른 천연추출물들(예컨대, 파고지 추출물 등) 및 공지의 미백물질(예컨대 감초 추출물)을 혼합하여 제조된 혼합 추출물을 함유하면 미백 효과면에서 상승효과가 나타난다. 또한, 본 발명에 따른 천연식물 추출물들은 제품의 안정성에 영향을 미치지 않는 농도에서 색소침착을 감소시키는 효과가 있으므로 미백화장료에 유효농도로 사용할 수 있다.As can be seen from the examples and experiments according to the present invention, the composition for whitening containing a myrrh extract or a mixed extract according to the present invention is very safe when used in humans and is excellent in reducing pigmentation. On the other hand, synergistic effect in terms of the whitening effect is shown by containing a mixed extract prepared by mixing the myrrh extract and other natural extracts (such as pagoji extract, etc.) and known whitening substances (such as licorice extract). In addition, natural plant extracts according to the present invention can be used in effective whitening cosmetics because it has an effect of reducing pigmentation at a concentration that does not affect the stability of the product.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019990037387A KR100328975B1 (en) | 1999-09-03 | 1999-09-03 | Whitening composition including the myrrh extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019990037387A KR100328975B1 (en) | 1999-09-03 | 1999-09-03 | Whitening composition including the myrrh extract |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020010052430A Division KR100345225B1 (en) | 2001-08-29 | 2001-08-29 | Whitening cosmetic composition including the extract of the fruit of Evodia officinalis, E. rutaecarpa |
KR1020010052428A Division KR100348936B1 (en) | 2001-08-29 | 2001-08-29 | Whitening cosmetic composition including the extract of the seed of Psoralea corylifolia and the extract of the fruit of Evodia officinalis, E. rutaecarpa |
KR1020010052431A Division KR100345226B1 (en) | 2001-08-29 | 2001-08-29 | Whitening cosmetic composition including the extract of the fruits of Melia azedarach or M. toosendan |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010026175A KR20010026175A (en) | 2001-04-06 |
KR100328975B1 true KR100328975B1 (en) | 2002-03-20 |
Family
ID=19610012
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019990037387A KR100328975B1 (en) | 1999-09-03 | 1999-09-03 | Whitening composition including the myrrh extract |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100328975B1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100422419B1 (en) * | 2001-09-26 | 2004-03-11 | 코스맥스 주식회사 | Whitening cosmetic composition containing herb extracts |
KR101107311B1 (en) * | 2008-12-19 | 2012-01-20 | 주식회사 백옥생 | Skin whitening composition comprising furanodienone |
KR101111252B1 (en) * | 2008-12-19 | 2012-02-22 | 주식회사 백옥생 | Skin whitening composition comprising herb extract |
KR20180053019A (en) * | 2016-11-11 | 2018-05-21 | 주식회사 바이오웨이 | Cosmetic composition having safety and superior moisturizing effect for skin |
KR20210085003A (en) * | 2019-12-30 | 2021-07-08 | 주식회사 유비아이코퍼레이션 | Cosmetic composition comprising Commiphora Myrrh and illite as an active ingredient |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010110001A (en) * | 2000-06-05 | 2001-12-12 | 최희진 | Cosmetics composition containing Psoralea corylifolia L. extracts |
KR100583792B1 (en) * | 2004-10-18 | 2006-05-26 | 주식회사 황토생활건강 | Cosmetic composition for whitening, anti-inflammation and anti-dendruff containing yellow soil and medicine herbs extract |
KR100833652B1 (en) * | 2006-12-28 | 2008-05-29 | 한국화학연구원 | Composition for preventing or treating a neurodegenerative disease comprising an extract from a seed of psoralea corylifolia inhibiting the activity of bace-1 or active ingredients thereof |
KR101782962B1 (en) * | 2011-01-08 | 2017-10-23 | 주식회사 케미메디 | Composition for treatment of leukemia and method of manufacturing extract from myrrh |
KR101454161B1 (en) * | 2013-10-30 | 2014-10-29 | 주식회사 해피콜 | Myrrha solution and myrrha aqueous solution and method for manufacturing the same and myrrha aqueous solution comprising product of manufacturing method therof |
KR102158780B1 (en) * | 2018-10-02 | 2020-09-22 | 주식회사 엘지생활건강 | Composition for improving skin comprising natural material extract |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR960006933A (en) * | 1994-08-24 | 1996-03-22 | 조문형 | Degreaser composition |
JPH0899859A (en) * | 1994-09-30 | 1996-04-16 | Kose Corp | Skin external agent |
KR960010005A (en) * | 1994-09-22 | 1996-04-20 | 장재헌 | Novel 2-chloro-3-arylamino-1,4-naphthoquinone derivatives, methods for their preparation and their use as platelet aggregation inhibitors |
JPH1171231A (en) * | 1997-08-28 | 1999-03-16 | Maruzen Pharmaceut Co Ltd | Skin whitening agent and skin whitening cosmetic |
CN1256913A (en) * | 1999-11-22 | 2000-06-21 | 陈曙 | Traditional Chinese medicinal beautifying cosmetics |
-
1999
- 1999-09-03 KR KR1019990037387A patent/KR100328975B1/en not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR960006933A (en) * | 1994-08-24 | 1996-03-22 | 조문형 | Degreaser composition |
KR960010005A (en) * | 1994-09-22 | 1996-04-20 | 장재헌 | Novel 2-chloro-3-arylamino-1,4-naphthoquinone derivatives, methods for their preparation and their use as platelet aggregation inhibitors |
JPH0899859A (en) * | 1994-09-30 | 1996-04-16 | Kose Corp | Skin external agent |
JPH1171231A (en) * | 1997-08-28 | 1999-03-16 | Maruzen Pharmaceut Co Ltd | Skin whitening agent and skin whitening cosmetic |
CN1256913A (en) * | 1999-11-22 | 2000-06-21 | 陈曙 | Traditional Chinese medicinal beautifying cosmetics |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100422419B1 (en) * | 2001-09-26 | 2004-03-11 | 코스맥스 주식회사 | Whitening cosmetic composition containing herb extracts |
KR101107311B1 (en) * | 2008-12-19 | 2012-01-20 | 주식회사 백옥생 | Skin whitening composition comprising furanodienone |
KR101111252B1 (en) * | 2008-12-19 | 2012-02-22 | 주식회사 백옥생 | Skin whitening composition comprising herb extract |
KR20180053019A (en) * | 2016-11-11 | 2018-05-21 | 주식회사 바이오웨이 | Cosmetic composition having safety and superior moisturizing effect for skin |
KR101986364B1 (en) * | 2016-11-11 | 2019-06-07 | 주식회사 바이오웨이 | Cosmetic composition having safety and superior moisturizing effect for skin |
KR20210085003A (en) * | 2019-12-30 | 2021-07-08 | 주식회사 유비아이코퍼레이션 | Cosmetic composition comprising Commiphora Myrrh and illite as an active ingredient |
KR102360617B1 (en) | 2019-12-30 | 2022-02-09 | (주)유비아이코퍼레이션 | Cosmetic composition comprising Commiphora Myrrh and illite as an active ingredient |
Also Published As
Publication number | Publication date |
---|---|
KR20010026175A (en) | 2001-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Devi et al. | Study of antioxdant, antiinflammatory and woundhealing activity of extracts of Litsea glutinosa | |
CN106455651A (en) | Topical compositions and methods for reducing oxidative stress | |
KR101387308B1 (en) | Skin whitening composition by using of dendropanax morbifera ferment extract | |
KR100328975B1 (en) | Whitening composition including the myrrh extract | |
KR101824770B1 (en) | Anti-wrinkle cosmetic composition comprising essentially Polygonum multiflorum adventitious extract | |
KR20090017282A (en) | Cosmetic composition containing a medicinal liquor extracts of traditional oriental herb complex with the antioxidant effect | |
KR100820237B1 (en) | A cosmetic composition comprising an extract of crude drug complex showing anti-oxidant and moisturizing activities | |
KR100544024B1 (en) | Skin whitening compound | |
KR100345226B1 (en) | Whitening cosmetic composition including the extract of the fruits of Melia azedarach or M. toosendan | |
KR20110128384A (en) | The composition material and the manufacturing process for skin-wrinkle, moisture and skin-lightening uses by midam-kyungokko | |
KR100515418B1 (en) | Anti-wrinkle cosmetics composition comprising natural herb extracts | |
KR100348822B1 (en) | Cosmetic compositions for skin whitening containing extract of galenical medicines | |
KR100345225B1 (en) | Whitening cosmetic composition including the extract of the fruit of Evodia officinalis, E. rutaecarpa | |
KR20010077652A (en) | Compositions for whitening cosmetics | |
KR20050092313A (en) | Skin whitening cosmetic containing a herb extract with inhibitory activity of melanin formation | |
KR100348936B1 (en) | Whitening cosmetic composition including the extract of the seed of Psoralea corylifolia and the extract of the fruit of Evodia officinalis, E. rutaecarpa | |
KR20060025630A (en) | Cosmetic composition for skin improvement including sprout extract | |
KR20080049234A (en) | Cosmetic composition containing extracts of impatiens balsamina l. for controlling anti-acne or anti-comedone | |
KR20020084429A (en) | Cosmetic composition containing a Rosa davurica Pall extracts for application to the skin | |
KR20130070062A (en) | Cosmetic composition for anti-oxidation or skin whintening containing extract of medicinal herbs mixture | |
KR20030039726A (en) | A cosmetic composition containing an extract of petasites japonicus | |
KR100500642B1 (en) | Whitening containing extract from Anthriscus sylvestris or Lepidium apetalum Wild. | |
KR101017586B1 (en) | Cosmetic composition for skin whitening | |
Chiru | Phytochemical study of Centaurea cyanus L | |
CN115212157B (en) | Preparation method and application of natural plant extract compound herbal raw material for whitening, removing freckles and resisting aging |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
A107 | Divisional application of patent | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20060216 Year of fee payment: 5 |
|
LAPS | Lapse due to unpaid annual fee |